Oncogenic mutations in ras genes frequently occur in patients with myeloid disorders and in these patients erythropoiesis is often affected. Previously we showed that expression of oncogenic H-ras in purified mouse primary fetal liver erythroid progenitors blocks terminal erythroid differentiation and supports Epo-independent proliferation. As a first step in understanding the underlying molecular mechanisms we examined the signaling pathways downstream of Ras in primary erythroid cells. We found that three major pathways are abnormally activated by oncogenic H-ras: Raf/ERK, PI3-kinase/Akt and RalGEF/RalA. However, only constitutive activation of the MEK/ERK pathway alone could recapitulate all of the effects of oncogenic H-ras expression in blocking erythroid differentiation and inducing Epo-independent proliferation. While expression of a constitutively active Akt kinase (ca.Akt) in erythroid progenitors does not significantly affect erythroid differentiation in the presence of erythropoietin (Epo), coexpression of ca.Akt together with a constitutively active MEK causes prolonged Epo-independent proliferation of erythroid progenitors in addition to a block in differentiation. Moreover, the effects of oncogenic H-ras expression on primary erythroid cells are blocked by the addition of U0126, a specific inhibitor of MEK1/2, allowing normal terminal erythroid proliferation and differentiation. Our data suggest that the interruption of constitutive MEK/ERK signaling is a potential therapeutic strategy to correct impaired erythroid differentiation in patients with myeloid disorders.
Introduction
Ras signaling plays an important role in erythropoiesis, and K-ras -/and N-ras -/-/ K-ras +/mice die at early embryonic stages with anemia 1 . Although apparent defects were identified in both hematopoietic cells and supporting stromal cells, the cellular mechanisms underlying this phenotype remain elusive 1, 2 . Additionally, mutations in the N-and K-ras genes that create constitutively active/oncogenic Ras proteins are frequently identified in patients with myeloid disorders 3, 4 . In these diseases the erythroid lineage is often affected, suggesting a role for altered Ras signaling in the dysregulated erythropoiesis seen in these patients. We and others showed that transduction of human or murine erythroid progenitors with oncogenic Ras results in hyperproliferation and defective differentiation leading to reduced production of mature erythrocytes [5] [6] [7] .
Consistent with these findings, a mouse line carrying a conditional oncogenic K-ras allele developed similar phenotypes when the oncogenic K-ras allele was activated somatically 8 . These data support the notion that oncogenic Ras directly impairs erythropoiesis in patients with myeloid disorders but the underlying mechanisms are largely unknown.
The effects of oncogenic Ras are mediated by its ability to activate multiple downstream effector proteins. The contribution of each individual effector to the effects of oncogenic Ras has been evaluated mainly in rodent fibroblast systems such as NIH 3T3 and mouse embryonic fibroblast cells. In these cells, activation of the Raf/MEK/ERK pathway is critical for Ras-mediated transformation. Like oncogenic Ras, expression of For personal use only. on October 3, 2017. by guest www.bloodjournal.org From constitutively active Raf or MEK proteins leads to tumorigenic transformation of NIH 3T3 cells [9] [10] [11] [12] . In addition, inhibition of the Raf/MEK/ERK pathway by dominantnegative mutants or pharmacologic inhibitors blocks Ras-mediated transformation [13] [14] [15] [16] [17] [18] [19] [20] .
Although constitutive activation of the PI3-kinase/Akt or RalGEF/RalA pathway alone fails to transform NIH 3T3 cells, their coexpression with activated Raf enhances the rate and extent of cell transformation [21] [22] [23] .
Due to the difficulty in purifying large numbers of primary erythroid progenitors, the signaling pathways abnormally activated by oncogenic Ras have not been extensively studied in these cells. For the same reason the contribution of each individual Ras downstream signaling pathway to the effects of oncogenic Ras has not been evaluated in these cells. Recently, we developed a method to isolate large numbers of erythroid progenitors from mouse fetal livers by an easy single-step purification involving removal of all TER119 + cells 5 . Using these erythroid progenitors we developed an in vitro culture system that supports their normal terminal proliferation and erythroid differentiation 5 .
During the first day in culture these cells undergo several divisions and upregulate the transferrin receptor. Additional divisions occur during the second day as the cells induce TER119 expression, downregulate the transferrin receptor, induce hemoglobin synthesis, and enucleate. Overall the cell number increases 15-20 fold. We monitor erythroid differentiation step by step and quantitatively using a flow cytometry analysis on living cells, following expression of the transferrin receptor (CD71) and the TER119 antigen.
Since we can express any desired protein in these progenitors using a bicistronic retrovirus, this is a valuable system to study the functions of any desired signaling For personal use only. on October 3, 2017. by guest www.bloodjournal.org From molecule in erythroid differentiation. Using this system we found that oncogenic H-ras blocks terminal erythroid differentiation and supports Epo (erythropoietin)-independent proliferation in primary erythroid progenitors 5 . As a first step in understanding the underlying mechanisms, we investigated signaling pathways downstream of H-ras in primary erythroid progenitors.
Here we report that oncogenic H-ras expression constitutively activates the p44/42 ERK, Akt and RalA pathways in primary erythroid progenitors. Expression of constitutively active MEK1 (ca.MEK) is sufficient to recapitulate the effects of oncogenic H-ras in these cells. In addition, expression of ca.Akt but not ca.Rlf acts synergistically with ca.MEK in supporting Epo-independent growth of primary erythroid progenitors.
Moreover, the addition of U0126, a MEK1/2 specific inhibitor, to primary erythroid progenitors expressing oncogenic H-ras greatly reduces the activation level of the p44/42 ERK pathway. U0126 concomitantly inhibits Epo-independent growth and restores normal terminal erythroid differentiation.
Materials and methods

Cells and chemical inhibitors
The retrovirus packaging cell lines BOSC23 (a gift of Dr. Xiaowu Zhang, Whitehead Institute, Cambridge, MA) 24 Fetal liver cells were isolated from E12.5-E15.5 Balb/c (Jackson Laboratory, Bar Harbor, ME) embryos and mechanically dissociated by pipetting in PBS containing 2%FBS.
Single cell suspensions were prepared by passing the dissociated cells twice through 70 µm cell strainers. TER119cells were purified and cultured as previously described 5 .
U0126 (Calbiochem, San Diego, California) was dissolved in DMSO according to the manufacturer's instructions. The inhibitor was added into primary cell culture on Day 1.
For Western analyses, cells were harvested 6 hours after the addition of the inhibitor. For growth curve analysis, the inhibitor was replaced every 24 hours. 26 , were subcloned 5' to the IRES in the XZ201 and MICD4 retroviral vectors 5 .
Retroviral
Generation of retroviral supernatants and infection of primary cells
BOSC23 or 293T cells were seeded on 100-mm dishes one day before transfection. 4-9
µg of retroviral plasmid together with 1-3 µg of the pCL-Eco vector 27 were used to cotransfect BOSC23 or 293T cells by the FuGENE 6 Transfection Reagent (Roche, Indianapolis, IN) according to the manufacturer's protocol. The retroviral supernatants were collected 40-48 hours after transfection and stored in aliquots at -80°C freezer.
Purified TER119fetal liver cells were infected with retroviral constructs, plated on For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 7 fibronectin-coated plates, and cultured for two days in medium containing Epo exactly as described previously 5 .
Immunostaining and flow cytometric analysis of erythroid differentiation
Cultured cells were harvested and stained for CD71, TER119, and hCD4 (when infected with MICD4 constructs only) or TER119 and hCD4 (when infected with both XZ201 and MICD4 constructs) as previously described 5 . hCD4and hCD4 + cells were distinguished by staining mock-infected cells with the same protocol. Flow cytometry was carried out on a Becton Dickinson FACSCalibur (BD Biosciences, Franklin Lakes, NJ).
Cytospin preparations and histological staining
Between 20,000 and 40,000 in vitro cultured TER119cells were centrifuged onto slides for 3 minutes at 800 rpm (Cytospin 3; Shandon) and air dried. Cells were fixed in methanol for 2 minutes at -20°C and stained with 3,3'-diaminobenzidine Giemsa stains according to the manufacturer's recommendations (Sigma).
Cell cycle analysis
Retrovirally transduced TER119fetal liver cells were cultured in vitro for one day, and infected cells were stained and sorted by a FACS Moflo machine (Cytomation, Fort Collins, CO) based on their surface expression of the hCD4 marker inserted downstream of the IRES in the retroviral vector. The sorted cells were cultured for another day on fibronectin-coated wells. Cultured cells were then harvested and stained in Hypotonic Propidium Iodide (PI) solution (0.1% sodium citrate and 50 mg/ml PI). Flow cytometry For personal use only. on October 3, 2017. by guest www.bloodjournal.org From was carried out on a BD FACSCalibur machine and collected data was analyzed by ModFit software (Verity Software House, Inc., Topsham, ME).
In vitro growth assay
Retrovirally transduced TER119 fetal liver cells were cultured for one day and infected cells were sorted. Sorted cells were further maintained and counted as previously described 5 .
Immunoprecipitation and Western analysis
Retrovirally transduced cells were cultured overnight and starved in IMDM containing 
Results
Oncogenic H-ras constitutively activates the p44/42, Akt and RalA pathways in primary erythroid progenitors.
We first determined the signaling pathways constitutively activated by oncogenic H-ras (H-ras.V12 mutant) expression in mouse erythroid progenitors. In other cell lines transformed with the H-ras.V12 mutant three major pathways become constitutively activated: the Raf, PI3-kinase, and RalGEF pathways [reviewed in 28 ]. Thus we first focused on these pathways in H-ras.V12-transduced erythroid progenitors.
To this end we employed freshly isolated TER119 primary fetal liver cells; previously we showed that at least 85% of this population are erythroid progenitors and early erythroblasts 5 . These were infected either with a control retrovirus or a retrovirus encoding H-ras.V12. Since an infection efficiency of 60%-80% was routinely achieved, total cell lysates were prepared without further enrichment or purification of infected cells. After the cells were cultured for ~16 hours in the presence of serum and Epo, the extent of phosphorylation of p44/42 ERK, an indicator of its activation state, was the same in control vector-transduced cells and H-ras.V12 transduced cells (data not shown).
However, following depletion of both serum and Epo for 2 hours, p44/42 ERK remained active in H-ras.V12 transduced cells but not in the control cells. No difference was seen in the expression of total p44/42 ERK in the two populations of cells ( Figure 1) .
Similarly, H-ras.V12 expression induced constitutive activation of Akt in primary 10 erythroid cells; the basal activation level of Akt was extremely low in control vectortransduced cells ( Figure 1 ). In control cells deprived of serum and Epo, the GTP bound form of RalA was maintained at a significant basal level ( Figure 1 ). However, expression of H-ras.V12 caused a 2 to 3-fold elevation in the level of RalA-GTP ( Figure 1 ).
We also measured activation of other signaling pathways in these primary erythroid progenitors expressing H-ras.V12, including Stat5, p38 and JNK MAPKs. We failed to detect any abnormal activation of these pathways (data not shown). In summary, expression of oncogenic H-ras in primary fetal liver erythroid progenitors leads to constitutive activation of three major signaling pathways: p44/42 ERK, Akt and RalA.
Constitutively active MEK1 recapitulates the effects of oncogenic H-ras in mouse erythroid progenitors.
Previously we showed that expression of oncogenic H-ras (H-ras.V12 mutant) blocks terminal erythroid differentiation and triggers Epo-independent growth 5 . To determine how individual Ras pathways contribute to the effects of oncogenic H-ras.V12 in erythroid progenitors, we expressed constitutively active mutants of key signaling proteins in primary erythroid progenitors and examined their differentiation profiles, cell cycle profiles and Epo-independent growth.
We first analyzed the well-characterized H-ras double mutants that carry the V12 mutation and an additional mutation in the effector loop domain 23 21 . Each of these double mutants constitutively activates only one of the three Ras downstream signaling pathways. We introduced the double mutants individually (constitutive activation of one pathway) or two mutants simultaneously (constitutive activation of two pathways) into primary erythroid progenitors. To our surprise, none of these could recapitulate the effects of oncogenic H-ras on terminal erythroid differentiation and Epo-independent growth (data not shown). We then checked the extent that individual pathways were activated by the double mutants, for example p44/42 ERK activation by the Hras.V12;E38 mutant. Compared to H-ras.V12, expression of the H-ras.V12;E38 mutant resulted in very poor constitutive activation of p44/42 ERK (data not shown). We were not sure whether or not the failure to see any effects of expression of the H-ras.V12
double mutants alone or in any combination was caused by insufficient pathway activation in primary erythroid progenitors. Therefore, we switched to another group of constitutively active mutants. As shown in Figure 2 , constitutively active (ca) Raf activated the p44/42 ERK pathway to a level comparable to that of the oncogenic Hras.V12 mutant, whereas ca.MEK activated the p44/42 ERK pathway to a lesser extent.
Moreover, ca.MEK expression did not cause abnormal activation of either Akt or RalA in primary erythroid progenitors (data not shown). In contrast, expression of ca.Akt and ca.Rlf (a RalGEF) activated the Akt and RalA proteins, respectively to an even higher level than did H-ras.V12 ( Figure 2 ).
We then expressed each of these constitutively active mutant proteins individually in purified primary fetal liver TER119 erythroid progenitors. As before we used a bicistronic retroviral vector (MICD4) that also encodes a truncated hCD4 protein 5 . Thus, 12 cells expressing these signal transducing proteins simultaneously expressed hCD4 on their surface (hCD4 + cells). After two days in culture, the infected cells were first analyzed for erythroid differentiation profiles by the flow cytometry analysis described previously 5 . Essentially, cells were double-labeled for erythroid-specific TER119 and non erythroid-specific transferrin receptor (CD71). Five distinct populations of cells can be defined by their characteristic staining patterns: CD71 med TER119 low (R1, progenitor cells and proerythroblasts); CD71 high TER119 low (R2, proerythroblasts and early basophilic erythroblasts); CD71 high TER119 high (R3, early and late basophilic erythroblasts); CD71 med TER119 high (R4, chromatophilic and orthochromatophilic erythroblasts); and CD71 low TER119 high (R5, late orthochromatophilic erythroblasts and reticulocytes). Next we examined the cell cycle progression in cells expressing individual constitutively active proteins, after selecting the cells that expressed the GFP marker and thus the protein coexpressed by the retroviral vector . As expected for terminally differentiated cells, by the end of the two day culture period ~ 82% of erythroid cells expressing GFP only (control vector) had permanently exited the cell cycle and accumulated in the G 1 phase ( 
Constitutive activation of both MEK and Akt in primary erythroid progenitors supports more extensive Epo-independent growth than does oncogenic H-ras.
We further assessed the contribution of H-ras downstream signaling pathways by simultaneously expressing two constitutively active mutant signaling proteins in primary erythroid progenitors. In NIH 3T3 and other cell lines, constitutive activation of any two Ras downstream signaling pathways recapitulates the effects of oncogenic H-ras (Hras.V12 mutant) expression at least to some extent (e.g. stimulation of foci formation, but less efficiently than H-ras.V12) 23 21 . We were interested to know whether this is the case in primary erythroid progenitors.
To this end we expressed all three possible combinations of two constitutively active mutant signaling proteins, ca.MEK, ca.Akt and ca.Rlf, in TER119fetal liver erythroid progenitor-enriched cells. To select for double-infected cells we used two bicistronic retroviral constructs encoding different markers, GFP and hCD4. Doubly infected cells (GFP + hCD4 + ) were sorted one day after infection, then cultured for an additional day on 
Inhibition of the MEK/ ERK pathway restores normal differentiation in erythroid progenitors expressing oncogenic H-ras.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Constitutive activation of the MEK/ERK pathway in primary erythroid progenitors is sufficient to mimic the effects of oncogenic H-ras.V12 expression. Next we wanted to know whether constitutive activation of this pathway is essential for the proliferative and anti-differentiation effects of oncogenic Ras. To this end TER119 fetal liver cells were infected with the bicistronic retrovirus encoding H-ras.V12. After one day in culture, we added a MEK1/2 specific inhibitor, U0126 and placed the cells in medium lacking Epo.
As expected, U0126 greatly reduced the phosphorylation level of p44/42 ERK in erythroid progenitors expressing H-ras.V12 ( Figure 6A ) but exhibited no effects on Akt and RalA activation in these cells (data not shown). When these cells were cultured further in the presence of U0126 (with replacement of U0126 every 24 hours), the number of total viable cells peaked around 2 to 3 days ( Figure 6B ). As before, cells expressing H-ras.V12 but cultured in the presence of DMSO (vehicle control) proliferated actively for 6 to 7 days. Thus, U0126 inhibited Epo-independent growth of erythroid progenitors expressing H-ras.V12.
We further investigated the cellular mechanisms underlying the U0126-mediated inhibition of Epo-independent growth in erythroid progenitors expressing H-ras.V12. We examined the erythroid differentiation profile, cell cycle profile, and extent of apoptosis rate every 24 hours. On Day 2, we found that U0126 exerted a mild inhibition of cell cycle progression on cells expressing H-ras.V12 (data not shown and see Discussion).
The apoptotic rate in cells cultured in the presence of U0126 was similar to that in vehicle control cells (data not shown). Importantly, in the presence of U0126 ~60% of H-ras.V12
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From expressing cells underwent apparently normal erythroid differentiation and became TER119 + (R3 -R5) cells ( Figure 7A ). In contrast, in the absence of U0126 ~60% of Hras.V12 transduced cells remained undifferentiated as TER119-negative (R1 + R2) cells.
On Day3, we examined the H-ras.V12 transduced cells by Benzidine-Giemsa staining.
Benzidine stains for hemoglobin, whose elevated expression is a hallmark of terminal erythroid differentiation. When cultured in the absence of U0126, H-ras.V12 transduced cells displayed a morphology characteristic of undifferentiated erythroid cells and were mainly benzidine-negative ( Figure 7B ). In contrast, when cultured in the presence of U0126, H-ras.V12 transduced cells displayed morphologies characteristic of differentiated erythroid cells ( Figure 7B ). Most of them had differentiated into late orthochromatophilic erythroblasts and enucleated reticulocytes, all of which were benzidine-positive. The sizes of the differentiated reticulocytes were comparable to those of reticulocytes freshly isolated from fetal livers (data not shown). Consistent with their morphologies, over 80% of the remaining nucleated cells had exited the cell cycle and accumulated in the G 1 phase (data not shown). These data suggest that the MEK/ERK pathway is essential for H-ras.V12-mediated effects in primary erythroid progenitors.
Blocking constitutive activation of this pathway by U0126 inhibited Epo-independent growth of erythroid cells expressing H-ras.V12 and restored normal erythroid differentiation.
Discussion
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Here we showed that expression of oncogenic H-ras (H-ras.V12) abnormally activates three major downstream signaling pathways in primary erythroid cells. Among these constitutive activation of the MEK/ERK pathway is the key mediator of the effects of Hras.V12 expression in erythroid progenitors: Expression of ca.MEK blocked terminal erythroid differentiation and triggered Epo-independent growth, closely resembling the effects of H-ras.V12 (Figure 3 and 4 ). Our findings are consistent with previous studies performed in human acute myelogenous leukemia (AML) cell lines and primary leukemic blasts, in which the ERK pathway is constitutively activated in majority of the cases [reviewed in 29, 30 ]. These data suggest that constitutive activation of the MEK/ERK pathway is sufficient to cause impaired erythropoiesis in patients with myeloid disorders.
However, unlike the case in NIH 3T3 cells, ca.Raf, which constitutively activates the p44/42 ERK pathway to the same extent as does H-ras.V12 in primary erythroid cells ( Figure 2 ), failed to recapitulate the cell proliferation and anti-differentiation effects of Hras.V12 expression. Rather, ca.Raf expression induced massive cell death (data not shown). It is likely that primary erythroid progenitors are highly sensitive to the extent of ERK activation and that very high activation of this pathway alone may be toxic.
Alternatively, as previously reported that this construct confers a weak Ras-independent transforming ability 12 , ca.Raf may activate additional pathways that antagonize the constitutive activation of the p44/42 ERK.
Consistent with previous findings in NIH 3T3 cells, expression of ca.Akt or ca.Rlf alone did not mimic the effects of H-ras.V12 expression (Figure 3 and 4) . Erythroid cells expressing ca.Rlf showed a roughly normal differentiation profile, though the R5 cells, Figure 5 ). This opposing effect of ca.Rlf expression was likely not due to the higher activation level of the Rlf/RalA pathway than that seen in H-ras.V12-expressing cells (Figure 3) , as similar results were obtained when we used another constitutively active mutant (RalA.L71) that activates the RalA pathway less than does ca.Rlf 22, 31 (data not shown). Our observation is consistent with a previous report that Rlf opposes the action of Raf and PI3-kinase in PC12 cells 32 . . Some studies suggest that the PI3K/Akt pathway enhances and/or synergizes with the MEK/ERK signaling to provide a more robust growth-promoting signal, whereas other reports state that Akt is able to efficiently abrogate Raf activation of downstream signaling proteins. Different states of cell differentiation might account for the apparent discrepancies in these effects 33 . Alternatively, erythroid cells expressing a constitutively 21 active MEK/ERK pathway might undergo significant apoptosis, which could be prevented by constitutive activation of the Akt pathway, thus allowing a continuous increase in cell numbers in cells coexpressing ca.Akt and ca.MEK.
We used U0126, a specific MEK1/2 inhibitor, and a dominant-negative MEK mutant (dn.MEK) 17 to inhibit the ERK activation in erythroid cells expressing H-ras.V12
( Figure 6 and data not shown). In both cases, these agents greatly reduced ERK activation but showed no inhibition of Akt or p70 S6 kinase activation ( Figure 6 and data not shown). These agents efficiently blocked Epo-independent proliferation of H-Ras.V12
transduced cells and restored normal terminal erythroid differentiation ( Figure 6 and 7) .
The effects on erythroid differentiation induced by U0126 were similar to those induced by a farnesylation inhibitor, FTI-276, on H-Ras.V12 transduced cells (data not shown).
These observations are consistent with a previous report that a novel Ras farnesylation inhibitor (HR12) reverses the Ras-induced transformed phenotype through inhibition of the MEK/ERK pathway 34 .
Our results suggest the possibility of targeting the MEK/ERK signal transduction cascade in order to restore normal erythroid differentiation in myeloid leukemia patients.
Pharmacologic inhibitors of MEK have been used in human AML cell lines to inhibit the activation of ERK pathway [35] [36] [37] . These inhibitors inhibited cell growth and induced apoptosis, and also sensitized the cells to other chemotherapic drugs. However, our results are different from those obtained from AML cell lines. When examined 6-10 hours after addition, U0126 did not inhibit cell cycle progression in primary erythroid cells expressing oncogenic H-ras, though it showed a mild inhibition 24 hours after addition (data not shown). We hypothesize that U0126 does not inhibit the cell cycle progression per se. Rather, the cell cycle inhibition observed 24 hours after U0126 addition might be an indirect consequence of initiation of terminal erythroid differentiation in these cells. We did not observe any significant increase of apoptosis in H-ras.V12 transduced erythroid cells in the presence of U0126 (data not shown). Such differences on the effects of MEK/ERK inhibition between our data on primary erythroid progenitors with that obtained with AML cell lines is not surprising given the very different properties of these cells.
In addition to the three signaling pathways constitutively activated by oncogenic H-ras in primary erythroid progenitors, H-Ras.V12 appeared to inactivate certain protein phosphatases. We found (unpublished data, J. Zhang and H.F. Lodish) that in primary erythroid cells expressing H-ras.V12, p70 S6 kinase was phosphorylated (and thus activated) to the same level as in control cells. However, the phosphorylation level of its downstream target, S6 ribosomal protein, was much higher in cells transduced by Hras.V12 than that in cells transduced by the control vector. An elevated phosphorylation level of S6 ribosomal protein correlates well with an increase in translation of proteins involved in cell cycle progression and the translational machinery 38, 39 . Since the level of phosphorylation of any protein is regulated simultaneously by its kinase(s) and phosphatase(s), we reasoned that the phosphatase(s) that dephosphorylate S6 ribosomal protein must be inactivated by H-ras.V12 expression in primary erythroid progenitors. To test this, we treated primary erythroid progenitors transduced by control vector with okadeic acid, an inhibitor of protein phosphatases 1 and 2A 40 . The phosphorylation level of S6 ribosomal protein in these cells increased to a level comparable to that in cells transduced by H-ras.V12 (and untreated with okadeic acid; data not shown). This observation is consistent with a previous report that phosphatase PAC1 is downregulated in human acute leukemia cells 41 Freshly isolated fetal liver TER119 cells were infected with bicistronic retroviruses encoding hCD4 alone (control vector), H-ras.V12, constitutively active (ca) Raf, ca.MEK, ca.Akt, or ca.Rlf. The cells were cultured, harvested, and lysates analyzed exactly as described in the legend to Figure 1 . The extent of activation of each individual pathway by each ca mutant was compared to that induced H-ras.V12. ca.Akt was created by the deletion of its PH domain and the addition of a src myristoylation signal at its Nterminus 25 . Therefore, the size of ca.Akt protein is smaller than that of wild-type Akt.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Freshly isolated fetal liver TER119cells were infected with a bicistronic retrovirus encoding H-ra.V12 and hCD4 and cultured as described in Figure 6 .
(A) After two days in culture in the absence or presence of U0126, erythroid differentiation profiles were analyzed by FACS as described in Figure 3 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
